CJC-1295 No DAC + Ipamorelin 10MG
Find your strength. Choose your bundle.
59 in stock
Earn up to $6.00 back on this itemLazarus Pass · 1–5% store credit + free shipping protection · A$19.95/moA closer
look.
CJC-1295 (No DAC) + Ipamorelin — also written CJC 1295 or CJC1295 — is a dual-peptide research formulation that pairs a short-acting GHRH analogue (CJC-1295 No DAC) with a selective growth-hormone-releasing peptide (Ipamorelin, a ghrelin/GHS-receptor agonist).
In research it is used to study complementary signalling across the GHRH and ghrelin receptors within the growth-hormone axis.
Research details & references
Last reviewed:
Lazarus Labs supplies it in Australia as a 10 mg lyophilised reference material (5 mg + 5 mg) at ≥ 99 % purity, with a certificate of analysis for every lot. For research use only — not for human or veterinary use.
What is CJC-1295 + Ipamorelin?
Research context
CJC-1295 is a GHRH analogue and Ipamorelin is a growth-hormone secretagogue acting at the ghrelin (GHS) receptor; laboratories study the pair together because the two mechanisms are complementary — a common design in growth-hormone-axis and receptor-signalling research. Related GHRH-analogue and secretagogue compounds include Tesamorelin and Sermorelin.
Specifications
- Total concentration: 10 mg per vial
- Composition: CJC-1295 No DAC 5 mg + Ipamorelin 5 mg
- Purity: ≥ 99 %, confirmed by HPLC and LC-MS
- Form: white lyophilised powder
- Solubility: readily soluble in water (H₂O)
- Testing: every batch independently tested by Janoshik (HPLC + LC-MS)
- Documentation: third-party certificate of analysis per lot
- Intended use: in-vitro and laboratory research only
Quality & documentation
Every lot is independently tested by Janoshik Analytical, with a certificate of analysis reporting HPLC purity and LC-MS identity for your exact batch. For deeper background, see our CJC-1295 + Ipamorelin research overview.
Handling & storage
Store sealed and dry at 2–8 °C. After reconstitution, keep refrigerated and follow your laboratory’s own handling and stability procedures. Supplied for research use only — not for human or veterinary use.
Dispatch & supply in Australia
Ships from within Australia with tracked delivery, and every order includes the matching certificate of analysis.
Read the citation-backed research overview →
Cited research
- Raun K, Hansen BS, Johansen NL, et al European Journal of Endocrinology. 1998. PMID: 9849822.
- Davenport AP, Bonner TI, Foord SM, et al Pharmacological Reviews. 2005. PMID: 16382107.
- Alba M, Fintini D, Sagazio A, et al American Journal of Physiology - Endocrinology and Metabolism. 2006. PMID: 16822960.
- Ionescu M, Frohman LA Journal of Clinical Endocrinology & Metabolism. 2006. PMID: 17018654.
Primary literature, verified against PubMed. Cited for scientific reference only — no human-use indication is implied.
The finer
details.
Check the product format, available strengths and intended use.
- Product
- CJC-1295 No DAC + Ipamorelin 10MG
- Intended use
- Laboratory research only
- Documentation
- See COA tab for strength and batch reports
Read the report.
Know the batch.
Compare the product, strength and batch on your vial with the original laboratory document.
Lazarus batch report
- Batch
- LL-CJCIPA-0125
- Report
- #110541
- Tested
- 2026-08-07
Reports identify tested batches. The available reports do not establish which batch will be dispatched with your order.
WA dispatch.
Tracked delivery.
Orders are dispatched from Western Australia with tracking. Check the selected product's availability and any pre-order notice before ordering.
Pre-order items follow their stated dispatch estimate. Orders containing pre-order items ship together once everything is available.
Shipping details →



